文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

中国的CAR T细胞疗法:快速演进与光明前景

CAR T-cell therapies in China: rapid evolution and a bright future.
PubMed 文献 · Lancet Haematol · 2022-01-01

文章分析了中国CAR T临床试验范围(尤其血液肿瘤领域)、相关政策、企业与资本支持特点,并探讨了成就与挑战。

要点

  • 中国CAR T细胞疗法从2013年首批临床试验快速发展至2017年全球最大数量CAR T相关临床试验。
  • 政府支持、资本流入、大量患者需求、独特医疗体系及中国医师与科学家的努力共同推动了这一增长。

核心结论

  • 中国CAR T细胞疗法快速演进,得益于政府支持、资本流入、患者需求、医疗体系及医师科学家的努力,文章探讨其成就与挑战以促进细胞治疗发展及临床应用。

研究设计与样本

  • 本文为系列综述文章,概述中国CAR T细胞临床试验范围(尤其血液肿瘤领域),分析相关政策,总结企业与资本支持特点,并探讨成就与挑战。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell therapies have achieved remarkable success in the treatment of haematological malignancies. Over the past 9 years, the use of CAR T-cell therapies has expanded throughout China, from the first clinical trials of CAR T cells conducted in 2013, to the world's largest number of CAR T-cell-related clinical trials in 2017, to a cumulative US$2·37 billion in funding for cell therapy companies in 2021, and a significant growth in the number of CAR T-cell-related clinical trials and basic research. This strong increase in activity is the result of a culmination of factors in China: strong government support, capital inflow, large patient demand, a unique health-care system, and the efforts of Chinese physicians and scientists. This Series paper provides an overview of the scope of CAR T-cell clinical trials in China (especially in the field of haematological malignancies), analyses the relevant policies, summarises the characteristics of corporate and capital support, and explores the achievements and challenges of CAR T-cell therapy in China to provide a better understanding for further promoting the development of cellular therapy and its clinical application.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Hu Y, Feng J, Gu T, et al. CAR T-cell therapies in China: rapid evolution and a bright future. Lancet Haematol. 2022. PMID: 36455608. doi:10.1016/S2352-3026(22)00291-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。